ATC Group: N03AD01 Ethosuximide

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N03AD01 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N03 Antiepileptics
3 N03A Antiepileptics
4 N03AD Succinimide derivatives
5 N03AD01 Ethosuximide

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 1.25 g

Active ingredients in N03AD01

Active Ingredient Description
Aethosuximide

Ethosuximide is an anti-epileptic of the class of succinimides that apparently exerts multiple mechanisms of action. The activity of ethosuximide in absence type epilepsy seems to rely primarily on the inhibition of T-type calcium channels in the thalamus.

Medicines in this ATC group

United States (US)

Australia (AU)

Austria (AT)

Brazil (BR)

Canada (CA)

Estonia (EE)

France (FR)

Ireland (IE)

Japan (JP)

Lithuania (LT)

Malta (MT)

Mexico (MX)

Netherlands (NL)

New Zealand (NZ)

Poland (PL)

Romania (RO)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.